Cargando…

Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression

Expression of MYC is deregulated in a wide range of human cancers, and is often associated with aggressive disease and poorly differentiated tumor cells. Identification of compounds with selectivity for cells overexpressing MYC would hence be beneficial for the treatment of these tumors. For this pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenzel, Anna, Zirath, Hanna, Vita, Marina, Albihn, Ami, Henriksson, Marie Arsenian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223192/
https://www.ncbi.nlm.nih.gov/pubmed/22132187
http://dx.doi.org/10.1371/journal.pone.0027988
_version_ 1782217268140179456
author Frenzel, Anna
Zirath, Hanna
Vita, Marina
Albihn, Ami
Henriksson, Marie Arsenian
author_facet Frenzel, Anna
Zirath, Hanna
Vita, Marina
Albihn, Ami
Henriksson, Marie Arsenian
author_sort Frenzel, Anna
collection PubMed
description Expression of MYC is deregulated in a wide range of human cancers, and is often associated with aggressive disease and poorly differentiated tumor cells. Identification of compounds with selectivity for cells overexpressing MYC would hence be beneficial for the treatment of these tumors. For this purpose we used cell lines with conditional MYCN or c-MYC expression, to screen a library of 80 conventional cytotoxic compounds for their ability to reduce tumor cell viability and/or growth in a MYC dependent way. We found that 25% of the studied compounds induced apoptosis and/or inhibited proliferation in a MYC-specific manner. The activities of the majority of these were enhanced both by c-MYC or MYCN over-expression. Interestingly, these compounds were acting on distinct cellular targets, including microtubules (paclitaxel, podophyllotoxin, vinblastine) and topoisomerases (10-hydroxycamptothecin, camptothecin, daunorubicin, doxorubicin, etoposide) as well as DNA, RNA and protein synthesis and turnover (anisomycin, aphidicholin, gliotoxin, MG132, methotrexate, mitomycin C). Our data indicate that MYC overexpression sensitizes cells to disruption of specific pathways and that in most cases c-MYC and MYCN overexpression have similar effects on the responses to cytotoxic compounds. Treatment of the cells with topoisomerase I inhibitors led to down-regulation of MYC protein levels, while doxorubicin and the small molecule MYRA-A was found to disrupt MYC-Max interaction. We conclude that the MYC pathway is only targeted by a subset of conventional cytotoxic drugs currently used in the clinic. Elucidating the mechanisms underlying their specificity towards MYC may be of importance for optimizing treatment of tumors with MYC deregulation. Our data also underscores that MYC is an attractive target for novel therapies and that cellular screenings of chemical libraries can be a powerful tool for identifying compounds with a desired biological activity.
format Online
Article
Text
id pubmed-3223192
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32231922011-11-30 Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression Frenzel, Anna Zirath, Hanna Vita, Marina Albihn, Ami Henriksson, Marie Arsenian PLoS One Research Article Expression of MYC is deregulated in a wide range of human cancers, and is often associated with aggressive disease and poorly differentiated tumor cells. Identification of compounds with selectivity for cells overexpressing MYC would hence be beneficial for the treatment of these tumors. For this purpose we used cell lines with conditional MYCN or c-MYC expression, to screen a library of 80 conventional cytotoxic compounds for their ability to reduce tumor cell viability and/or growth in a MYC dependent way. We found that 25% of the studied compounds induced apoptosis and/or inhibited proliferation in a MYC-specific manner. The activities of the majority of these were enhanced both by c-MYC or MYCN over-expression. Interestingly, these compounds were acting on distinct cellular targets, including microtubules (paclitaxel, podophyllotoxin, vinblastine) and topoisomerases (10-hydroxycamptothecin, camptothecin, daunorubicin, doxorubicin, etoposide) as well as DNA, RNA and protein synthesis and turnover (anisomycin, aphidicholin, gliotoxin, MG132, methotrexate, mitomycin C). Our data indicate that MYC overexpression sensitizes cells to disruption of specific pathways and that in most cases c-MYC and MYCN overexpression have similar effects on the responses to cytotoxic compounds. Treatment of the cells with topoisomerase I inhibitors led to down-regulation of MYC protein levels, while doxorubicin and the small molecule MYRA-A was found to disrupt MYC-Max interaction. We conclude that the MYC pathway is only targeted by a subset of conventional cytotoxic drugs currently used in the clinic. Elucidating the mechanisms underlying their specificity towards MYC may be of importance for optimizing treatment of tumors with MYC deregulation. Our data also underscores that MYC is an attractive target for novel therapies and that cellular screenings of chemical libraries can be a powerful tool for identifying compounds with a desired biological activity. Public Library of Science 2011-11-23 /pmc/articles/PMC3223192/ /pubmed/22132187 http://dx.doi.org/10.1371/journal.pone.0027988 Text en Frenzel et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Frenzel, Anna
Zirath, Hanna
Vita, Marina
Albihn, Ami
Henriksson, Marie Arsenian
Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title_full Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title_fullStr Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title_full_unstemmed Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title_short Identification of Cytotoxic Drugs That Selectively Target Tumor Cells with MYC Overexpression
title_sort identification of cytotoxic drugs that selectively target tumor cells with myc overexpression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223192/
https://www.ncbi.nlm.nih.gov/pubmed/22132187
http://dx.doi.org/10.1371/journal.pone.0027988
work_keys_str_mv AT frenzelanna identificationofcytotoxicdrugsthatselectivelytargettumorcellswithmycoverexpression
AT zirathhanna identificationofcytotoxicdrugsthatselectivelytargettumorcellswithmycoverexpression
AT vitamarina identificationofcytotoxicdrugsthatselectivelytargettumorcellswithmycoverexpression
AT albihnami identificationofcytotoxicdrugsthatselectivelytargettumorcellswithmycoverexpression
AT henrikssonmariearsenian identificationofcytotoxicdrugsthatselectivelytargettumorcellswithmycoverexpression